Фармсинтез logo
Фармсинтез LIFE

Фармсинтез Cash Flow 2007-2026 | LIFE

Annual Cash Flow Фармсинтез

2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008 2007

Net Income

-207 M -733 M -527 M -1.81 B 59.8 M -2.84 B -945 M -398 M -199 M -153 M -54.5 M -7.08 M 19.1 M 14 M 2.12 M 16.9 M

Depreciation And Amortization of Intangible Assets

27.5 M 32 M 44.4 M 25.9 M 54.6 M 50.7 M 69.7 M 31.7 M 36.2 M 22.9 M 27.3 M 23.9 M - - - -

Deferred Income Tax

- - - - - - - - - - - - - - - -

Stock Based Compensation

- - - - - - - - - - - - - - - -

Change In Working Capital

95.4 M -11.4 M -23.3 M -49.4 M 319 M 623 M -173 M 193 M -617 M -188 M -95.8 M 44.8 M - - - -

Other Working Capital

95.4 M -798 -102 M -8.74 K - 645 M -199 M 246 M -521 M -161 M -37.7 M 17.7 M - - - -

Other Non Cash Items

81.2 M 650 M 273 M 1.74 B -59.8 M 2.03 B 471 M -30.2 M -61.8 M -34.7 M 6.62 M -8.03 M -19.1 M -14 M -2.12 M -16.9 M

Investments In Property Plant And Equipment

-3.47 M -279 K -9.68 M -14.5 M -19.4 M -24.3 M -33.6 M -14.6 M -81.2 M -125 M -73.2 M -101 M -13.9 M -5 M -3.78 M -

Acquisitions Net

- - - - - -14.8 M -46.5 M -6.83 M -692 K -82 K - -15.1 M - - - -

Purchases Of Investments

- - - - -350 K -53.1 M -64.3 M -6.83 M - -50 M -158 K -118 K - - - -

Sales Maturities Of Investments

- - - - - 54.5 M - - - 72.4 M - - - - - -

Other Investing Activites

-1 M -1.62 M - 37.3 M - 15.8 M 4.16 M 1.2 M -85.1 M 1.36 M -49.4 M -32.6 M -3.49 M -500 K 14 K -

Net Cash Used For Investing Activites

-4.47 M -1.9 M -9.68 M 22.8 M -350 K -21.9 M -75.9 M -20.2 M -167 M -101 M -123 M -148 M -17.4 M -5.5 M -3.77 M -

Debt Repayment

-19 M 69.4 M 94.9 M 144 M -1.5 M - 18.1 M -4.18 M - - -2.71 M -324 K -23.5 M -4.47 M 21.2 M -

Common Stock Repurchased

- - - - - - - - - - - -50 M - - - -

Dividends Paid

- - - - - - - - - - - - - - - -

Other Financing Activites

-6.68 M -1.31 M -3.32 M -3.98 M - 33.5 M -5.77 M -8.61 M -69.6 M -281 M - - -475 M - - -

Net Cash Used Provided By Financing Activities

-1.97 M 68.1 M 179 M 138 M -1.5 M 33.5 M 1.27 B -12.8 M 259 M 889 M -2.71 M -50.3 M 29.5 M -4.47 M 21.2 M -

Effect Of Forex Changes On Cash

3.68 M 1.37 M 7.05 M 150 K 13.6 M 73.9 M -254 M 133 M 355 M 2.08 M - - - - - -

Net Change In Cash

-6.12 M 4.88 M -56.5 M 64.1 M -3.72 M -51.9 M 364 M -104 M -394 M 436 M - - -10.4 M 18.5 M -2.63 M 5.1 M

Cash At End Of Period

9.17 M 15.3 M 10.4 M 64.3 M 233 K 327 M 371 M 7.39 M 111 M 505 M 68.7 M 312 M 11.6 M 22 M 3.49 M 6.12 M

Cash At Beginning Of Period

15.3 M 10.4 M 66.9 M 233 K 3.96 M 379 M 7.39 M 111 M 505 M 68.7 M 312 M 11.6 M 22 M 3.49 M 6.12 M 1.02 M

Operating Cash Flow

-3.35 M -62.7 M -233 M -96.6 M -15.5 M -137 M -577 M -204 M -841 M -353 M -116 M 53.6 M - - - -

Capital Expenditure

-3.47 M -279 K -9.68 M -14.5 M -19.4 M -24.3 M -33.6 M -14.6 M -81.2 M -125 M -72.3 M -82.3 M -13.9 M -5 M -3.78 M -

Free Cash Flow

-6.82 M -63 M -242 M -111 M -34.8 M -162 M -611 M -218 M -922 M -478 M -189 M -28.7 M -13.9 M -5 M -3.78 M -

All numbers in RUB currency

Quarterly Cash Flow Фармсинтез

2023-Q2 2022-Q4 2022-Q2 2021-Q4 2021-Q2 2020-Q4 2020-Q2 2019-Q4 2019-Q2 2018-Q4 2018-Q2 2017-Q4 2017-Q2 2016-Q4 2016-Q2 2015-Q4 2015-Q2 2014-Q4 2014-Q2 2013-Q4 2013-Q2 2011-Q4 2011-Q2 2010-Q4 2010-Q2 2009-Q4 2009-Q2 2008-Q2 2008-Q4

Net Income

-164 K -140 K -67.4 K -445 M -252 M -417 M -108 M -1.77 B -40.5 M -31.5 K -386 K -1.02 M -1.51 M -1.15 M 512 K -71.8 K -283 K -126 K -79.1 K -38.4 M -29.7 M -3.54 M -3.54 M 19.1 M - - - - -

Depreciation And Amortization of Intangible Assets

12.2 K 15.8 K 11.7 K 15.9 M 16 M 26.3 M 18.1 M 419 K 25.5 M 27 K 27.6 K 21.7 K 29 K 34.1 K 37.8 K 15.5 K 16.2 K 24.2 K 12 K 5.98 M 12 M 11.9 M 11.9 M - - - - - -

Deferred Income Tax

- - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Stock Based Compensation

- - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Change In Working Capital

-116 K 15.9 K -27.7 K -36.3 M 24.9 M -66.7 M -58.1 M -71.6 M 22.3 M 108 K -21.2 K -105 K 216 K 108 K 6.18 K -78.5 K 152 K -603 K -32.3 K -47 M -94 M 22.4 M 22.4 M - - - - - -

Other Working Capital

- -12.7 K - -399 - -102 M - -4.37 K 7.25 M - - 3.28 K -3.28 K -933 933 907 1.64 K -517 280 -40.2 M -80.3 M 8.83 M 8.83 M - - - - - -

Other Non Cash Items

-77.9 K 128 K 60.4 K 498 M 192 M 334 M 150 M 1.88 B -16.2 M -180 K 344 K 1.11 M 1.11 M 578 K -516 K -23.5 K 69.3 K 252 K -289 K -8.93 M -64.9 M -4.02 M -4.02 M -19.1 M - - - - -

Investments In Property Plant And Equipment

-35 K -1.64 K -1.84 K -211 K -68 K -6.09 M -3.6 M -14.5 M - 4.59 K -23.9 K -6.49 K -2.96 K -9.4 K -1.62 K -13 K -1.65 K -42 K -39.2 K -31.3 M -62.6 M -50.3 M -50.3 M -6.95 M -6.95 M -1.25 M -2.5 M -1.89 M -946 K

Acquisitions Net

- - - - - - - - - - - -2.2 K 2.2 K 17.8 K - - - - - - - -7.55 M -7.55 M - - - - - -

Purchases Of Investments

- - - - - - - - - - -175 K -175 K -26.5 M -26.5 M - - - - - -12.5 M -25 M -59 K -59 K - - - - - -

Sales Maturities Of Investments

- - - - - - - - - - - - 27.3 M 27.3 M - - - - - - - - - - - - - - -

Other Investing Activites

154 -1 K - -1.62 M - - - - -24.1 M -28.7 K 28.7 K -12.7 K 289 -83.1 K 507 1.42 K -7.06 K -55.6 K -30.1 K 43.8 M 87.6 M -16.3 M -16.3 M 853 K -4.35 M 8.38 M 16.8 M -8.14 M -4.07 M

Net Cash Used For Investing Activites

-34.9 K -2.64 K -1.84 K -1.84 M -68 K -6.09 M -3.6 M -14.5 M -24.1 M -24.1 K 4.76 K -21.4 K -474 -74.8 K -1.12 K -11.5 K -8.71 K -97.6 K -69.3 K -25.7 M -51.4 M -74.2 M -74.2 M -6.09 M -11.3 M 7.13 M 14.3 M -10 M -5.02 M

Debt Repayment

- - 5.2 K - - 104 M -8.94 M - - - - - - 1.03 B - - - - - - - -162 K -162 K -23.5 M - - - - -

Common Stock Repurchased

- - - - - - - - - - - - - -3.95 M - - - -8 - - - -25 M -25 M - - - - - -

Dividends Paid

- - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Other Financing Activites

629 K -7.17 K - 40.1 M 28 M -785 K -27.2 M 98 M 41.6 M 73.3 K 90.6 M 48.8 K -30.5 M -2.45 B 48.1 K -8.91 K -3.89 K -66.5 K 325 K 225 M 450 M - - -464 M -11.3 M 7.13 M 14.3 M -10 M -5.02 M

Net Cash Used Provided By Financing Activities

629 K -7.17 K 5.2 K 40.1 M 28 M 130 M 49.2 M 98 M 41.6 M 73.3 K 45.3 K 48.8 K -15.3 K 1.22 M 48.1 K -8.91 K -3.89 K -66.5 K 325 K 225 M 450 M -25.2 M -25.2 M 40.8 M -11.3 M 7.13 M 14.3 M -10 M -5.02 M

Effect Of Forex Changes On Cash

-706 -3.16 K 6.84 K 246 439 5.1 K -1.58 K 3.07 K -58.5 28.3 K -14.6 K 90 K -16.1 K -343 K -88.5 K 174 K -40.9 K 341 K 14.8 K -4.25 M -8.51 M - - - - - - - -

Net Change In Cash

257 K -2.48 K 2.48 K 3.29 M 1.59 M -7.32 M -49.2 M 59.6 M 1.13 M 16 M -985 K -930 K -94.5 M -13 M -1.84 M 90.9 M -27.8 M -26 M -126 M 109 M 218 M - - -10.4 M -2.61 M 4.63 M 4.63 M -657 K -657 K

Cash At End Of Period

124 K - 2.48 K 15.3 M 12 M 10.4 M 17.7 M 66.9 M 1.18 M 16.1 M 4.1 K 58.2 K 193 K 81.7 M 6.58 K 92.8 M 12.3 K 1.85 M 387 K 126 M 252 M 312 M 312 M 11.6 M 2.9 M 5.51 M 5.51 M 874 K 874 K

Cash At Beginning Of Period

- 2.48 K - 12 M 10.4 M 17.7 M 66.9 M 7.32 M 58.2 K 58.2 K 989 K 989 K 94.6 M 94.6 M 1.85 M 1.85 M 27.8 M 27.8 M 126 M 17.2 M 34.4 M 11.6 M 11.6 M 22 M 5.51 M 874 K 874 K 1.53 M 1.53 M

Operating Cash Flow

-346 K 19.7 K -23 K -35.5 M -27.2 M -141 M -91.7 M -23.9 M -45 M -76.9 K -35.8 K 8.9 K -146 K -434 K 40.7 K -158 K -45.4 K -453 K -388 K -88.3 M -177 M 26.8 M 26.8 M - - - - - -

Capital Expenditure

-35 K -1.64 K -1.84 K -211 K -68 K -6.09 M -3.6 M -14.5 M - 4.59 K -23.9 K -6.49 K -2.96 K -9.4 K -1.62 K -13 K -1.65 K -42 K -39.2 K -31.3 M -62.6 M -41.1 M -41.1 M -6.95 M -6.95 M -1.25 M -2.5 M -1.89 M -946 K

Free Cash Flow

-381 K 18 K -24.8 K -35.7 M -27.3 M -147 M -95.3 M -38.4 M -45 M -72.3 K -59.8 K 2.42 K -149 K -443 K 39.1 K -171 K -47.1 K -495 K -428 K -120 M -239 M -14.4 M -14.4 M -6.95 M -6.95 M -1.25 M -2.5 M -1.89 M -946 K

All numbers in RUB currency

Cash Flow Statement is one of the three key financial reports of the company Фармсинтез, reflecting the actual cash inflows and outflows over a certain period. Unlike the income statement, which shows revenues and expenses on an accrual basis, the cash flow statement focuses on real cash flows — how much cash actually came into the company and how much was spent.

Main Sections of the Cash Flow Statement
  • Operating Activities
    This section reflects cash flows related to the company’s core operations: receipts from sales of goods and services, payments to suppliers, employee salaries, taxes, and other operating expenses. Positive cash flow from operating activities indicates the viability of the business and its ability to generate cash.
  • Investing Activities
    Shows cash movements related to the purchase and sale of long-term assets such as real estate, equipment, and investments in other companies. Negative cash flow here often indicates investments in growth, which can be a positive sign.
  • Financing Activities
    Reflects the inflow and outflow of cash related to raising and repaying capital: issuing shares, loans, dividend payments, and loan repayments. This section shows how the company finances its activities and distributes profits.

The cash flow statement is important for investors because it allows them to assess the company’s real liquidity, showing whether it has enough cash to cover current obligations and investments — this is critical for financial stability. Additionally, it helps analyze the quality of earnings, since profits reported in the income statement can be "paper" profits and may not reflect actual cash inflows; the cash flow statement reveals this difference. The presence of free cash is also crucial for evaluating the company’s ability to finance growth and pay dividends, which is important for investors. Attention should also be paid to prolonged negative cash flows from operating activities, as this may serve as a warning sign of potential problems with the core business.

Cash flow statements of other stocks in the Biotechnology sector

Issuer Price % 24h Market Cap Country
ARCA biopharma ARCA biopharma
ABIO
- 1052.0 % $ 415 M usaUSA
MorphoSys AG MorphoSys AG
MOR
- 2.43 % $ 254 M germanyGermany
Acorda Therapeutics Acorda Therapeutics
ACOR
- -24.86 % $ 820 K usaUSA
AbCellera Biologics AbCellera Biologics
ABCL
$ 3.55 -0.28 % $ 1.06 B canadaCanada
Adagene Adagene
ADAG
$ 3.91 -2.01 % $ 220 M chinaChina
Acasti Pharma Acasti Pharma
ACST
- 4.01 % $ 150 M canadaCanada
AC Immune SA AC Immune SA
ACIU
$ 3.32 6.07 % $ 229 M schweizSchweiz
I-Mab I-Mab
IMAB
- - $ 866 M chinaChina
Advaxis Advaxis
ADXS
- -9.65 % $ 45.9 M usaUSA
Biophytis SA Biophytis SA
BPTS
- -13.47 % $ 169 M franceFrance
Aeterna Zentaris Aeterna Zentaris
AEZS
- 5.93 % $ 314 M canadaCanada
AgeX Therapeutics AgeX Therapeutics
AGE
- -10.17 % $ 12.2 K usaUSA
ADC Therapeutics SA ADC Therapeutics SA
ADCT
$ 4.11 -2.61 % $ 105 M schweizSchweiz
Aeglea BioTherapeutics Aeglea BioTherapeutics
AGLE
- - $ 1.01 B usaUSA
Applied Genetic Technologies Corporation Applied Genetic Technologies Corporation
AGTC
- - $ 26.5 M usaUSA
Aptorum Group Limited Aptorum Group Limited
APM
$ 0.79 0.04 % $ 4.31 M chinaChina
Midatech Pharma plc Midatech Pharma plc
MTP
- -18.52 % $ 27.3 M britainBritain
Adverum Biotechnologies Adverum Biotechnologies
ADVM
- - $ 86.2 M usaUSA
argenx SE argenx SE
ARGX
$ 706.03 0.39 % $ 25 B niderlandNiderland
Alterity Therapeutics Limited Alterity Therapeutics Limited
ATHE
$ 3.34 -7.48 % $ 8.04 B australiaAustralia
Ascendis Pharma A/S Ascendis Pharma A/S
ASND
$ 228.06 -1.28 % $ 5 B danmarkDanmark
Akero Therapeutics Akero Therapeutics
AKRO
- - $ 3.67 B usaUSA
Akouos Akouos
AKUS
- 0.23 % $ 488 M usaUSA
Albireo Pharma Albireo Pharma
ALBO
- -0.23 % $ 916 M usaUSA
Acer Therapeutics Acer Therapeutics
ACER
- 2.71 % $ 14 M usaUSA
Can-Fite BioPharma Ltd. Can-Fite BioPharma Ltd.
CANF
$ 3.43 -4.19 % $ 7.46 B israelIsrael
Allena Pharmaceuticals Allena Pharmaceuticals
ALNA
- 3.16 % $ 1.9 M usaUSA
Aileron Therapeutics Aileron Therapeutics
ALRN
- 10.36 % $ 9.8 M usaUSA
AlloVir AlloVir
ALVR
- 4.14 % $ 49.1 M usaUSA
Anika Therapeutics Anika Therapeutics
ANIK
$ 14.51 1.04 % $ 213 M usaUSA
Aptinyx Aptinyx
APTX
- -39.0 % $ 4.57 M usaUSA
Applied Molecular Transport Applied Molecular Transport
AMTI
- - $ 10.1 M usaUSA
Aptose Biosciences Aptose Biosciences
APTO
- -45.71 % $ 1.2 M canadaCanada
Arcturus Therapeutics Holdings Arcturus Therapeutics Holdings
ARCT
$ 6.39 -3.62 % $ 175 M israelIsrael
BioNTech SE BioNTech SE
BNTX
$ 94.86 4.77 % $ 27.2 B germanyGermany
CureVac N.V. CureVac N.V.
CVAC
- - $ 867 M germanyGermany
Aravive Aravive
ARAV
- -13.39 % $ 1.45 M usaUSA
Burford Capital Limited Burford Capital Limited
BUR
$ 8.28 2.86 % $ 1.34 B britainBritain
Athira Pharma Athira Pharma
ATHA
- - $ 269 M usaUSA
Athersys Athersys
ATHX
- 3.77 % $ 22.4 M usaUSA
Actinium Pharmaceuticals Actinium Pharmaceuticals
ATNM
$ 1.14 2.7 % $ 34.3 M usaUSA
Avenue Therapeutics Avenue Therapeutics
ATXI
- -52.27 % $ 4.45 M usaUSA
Autolus Therapeutics plc Autolus Therapeutics plc
AUTL
$ 1.51 - $ 385 M britainBritain
AVEO Pharmaceuticals AVEO Pharmaceuticals
AVEO
- - $ 521 M usaUSA
Atea Pharmaceuticals Atea Pharmaceuticals
AVIR
$ 6.13 1.32 % $ 500 M usaUSA
AVROBIO AVROBIO
AVRO
- 1083.1 % $ 745 M usaUSA
Equillium Equillium
EQ
$ 2.15 -7.33 % $ 74.7 M usaUSA